Previous 10 | Next 10 |
Viela Bio is an AstraZeneca-MedImmune spinoff. It has one approved drug and a long tailed pipeline. Their next catalyst is three to four years away. For further details see: Viela Bio: Startup With A Head Start
The following slide deck was published by Viela Bio, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Viela Bio, Inc. 2020 Q3 - Results - Earnings Call Presentation
Image source: The Motley Fool. Viela Bio Inc (NASDAQ: VIE) Q3 2020 Earnings Call Nov 10, 2020 , 5:00 p.m. ET Operator Continue reading For further details see: Viela Bio Inc (VIE) Q3 2020 Earnings Call Transcript
Viela Bio, Inc. (VIE) Q3 2020 Earnings Conference Call November 10, 2020, 05:00 PM ET Company Participants Mitchell Chan - CFO Bing Yao - Chairman and CEO Jörn Drappa - Chief Medical Officer and Head R&D Bill Ragatz - SVP, Head Commercial Conference Call Participants Seamus Fernandez...
VIELA BIO (VIE): Q3 GAAP EPS of -$0.69 beats by $0.08.Revenue of $2.32M misses by $1.36M.Viela had $387.5M in cash, equivalents, and investments and no outstanding debt.Press Release For further details see: VIELA BIO EPS beats by $0.08, misses on revenue
GAITHERSBURG, Md., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases, today reported financial results and provided program ...
-- VIB7734 potently depleted blood and tissue resident plasmacytoid dendritic cells, an important source of inflammatory mediators in autoimmune diseases -- -- Treatment with VIB7734 resulted in clinically significant reduction in CLASI-A , ...
GAITHERSBURG, Md., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases, today announced it will host a webcast and conference ...
The following slide deck was published by Viela Bio, Inc. in conjunction with this Read more ...
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 08/7/2020. Please visit our Tracking Ole Andreas Halvorsen&...
News, Short Squeeze, Breakout and More Instantly...
> A three-year partnership that aligns with Veolia’s mission to support organizations and industries that want to become more environmentally sustainable > Veolia will start with focusing on improving waste collection, increasing recycling percentages, providing sustainable w...
Clean Earth will partner with Veolia North America on a five-year agreement to provide guaranteed incineration capacity in a new state-of-the-art waste treatment facility in Gum Springs, Ark. The agreement provides reliable, predictable, safe, and efficient waste disposal for Clean Ea...
The array will produce over 250 million kilowatt hours of electricity – enough to power 25,000 homes – and offset carbon output by 105,000 tons over the next 25 years, making it the only hazardous waste treatment facility in U.S. to be fully energy self-sufficient Veolia N...